Abstract 2162P
Background
There is limited data on the quality of cancer information provided by ChatGPT and other artificial intelligence systems. In this study, we aimed to compare the accuracy of information about cancer pain provided by chatbots (chatGPT, perplexity, and chatsonic) based on the questions and answers contained in the the European Medical Oncology Association (ESMO) Patient Guide about cancer pain.
Methods
Twenty questions were selected from the questions available in the ESMO Patient Guide Cancer Pain. Medical oncologists with more than 10 years of experience compared responses from chatbots (ChatGPT, Perplexity, and Chatsonic) with the ESMO patient guide. The primary evaluation criteria for the quality of the responses were accuracy, patient readability, and stability of response. The accuracy of responses was evaluated using a three-point scale: 1 for accuracy, 2 for a mixture of accurate and incorrect or outdated data, and 3 for wholly inaccurate. The Flesch-Kincaid readability (FKr) grade was used to measure readability. Stability of responses was evaluated whether the model’s accuracy is consistent across different answers to the same question.
Results
Chatbots were more difficult to read than the ESMO patient guideline (FKr= 9.6 vs. 12.8, p= 0.072). Among the chatbots, perplexity had the easiest readability (FKr= 11.2). In the accuracy evaluation, the percentage of overall agreement for accuracy was 100% for ESMO answers and 96% for ChatGPT outputs for questions (k= 0.03, standard error= 0.08). Among the chatbots, the most accurate information was obtained with chatGPT.
Table: 2162P
Comparison of ESMO and chatbots in terms of readibility and accuracy
ESMO | Chatbots | ||||
ChatGPT | Perplexity | Chatsonic | p-value | ||
Readibility (FKr grade) | 9.6 Easily understood | 13.4 Difficult to read | 11.2 Fairly difficult to read | 13.9 Difficult to read | 0.072 |
Accuracy | %100 | %96 | %86 | % 90 | 0.037 |
Conclusions
The results suggest that ChatGPT provides more accurate information about cancer pain compared with other chatbots.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Gazi University Ethic Commitee.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2184TiP - Extensive cardiovascular characterization and follow-up of patients receiving immune checkpoint inhibitors: A prospective multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 07
2185TiP - Belgian FORX trial: FOod interventions to Reduce immunotherapy toXicity
Presenter: Marthe Verhaert
Session: Poster session 07
2186P - KN046 in patients with thymic carcinoma: A prospective, single-arm, multi-centre, phase II study
Presenter: Wentao Fang
Session: Poster session 07
2187P - Efficacy and safety of gemcitabine as maintenance treatment in unresectable malignant pleural mesothelioma: A phase II randomized study
Presenter: Mohamed Emam Sobeih
Session: Poster session 07
2188P - First-line combination of toripalimab and chemotherapy in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: hui'yang shi
Session: Poster session 07
2189P - Combining SBRT with GM-CSF and Peg-IFNα to induce abscopal effects in previously treated patients with stage IV thymic tumors
Presenter: Boyan Wang
Session: Poster session 07
2190P - First-line atezolizumab in combination with platinum etoposide in patients with metastatic lung large cell neuroendocrine carcinoma (LCNEC)
Presenter: Georgios Evangelou
Session: Poster session 07
2191P - Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting
Presenter: Sabine Schmid
Session: Poster session 07
2192P - Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real-world setting
Presenter: Abhenil Mittal
Session: Poster session 07
2193P - Real-world evidence of the impact of immunotherapy (IT) on overall survival (OS) of patients (p) with malignant pleural mesothelioma (MPM) adjusted for tumor histology
Presenter: Susana Cedres Perez
Session: Poster session 07